CC BY
7Central Asian Research Journal For Interdisciplinary Studies (CARJIS)
ISSN (online): 2181-2454 Volume 2 | Issue 10 |October, 2022 | SJIF: 5,965 | UIF: 7,6 | ISRA: JIF 1.947 | Google Scholar |
www.carjis.org DOI: 10.24412/2181-2454-2022-10-187-191
TREATMENT OF GENITAL AND LABIAL HERPES
Mavjuda Raimovna Baratova
Samarkand State Medical University Department of Skin and Venereal Diseases
Samarkand
ABSTRACT
This article summarizes the study of a total of 146 patients under observation, there were 63 men, 83 women. -50 years -23, over 50 years - 4. According to the PCR study, HSV-1 was detected in 30 (20.5%) patients, HSV-2 in 49 (33.5%), HSV-1 + HSV- 2 in 23 (15.8%), HSV without type identification in 18 (12.3%), a negative result was obtained in 6 (4.1%), no study was conducted, in 20 (13.8%) patients. Genital herpes was in 115 patients, labial herpes in 31 patients. The duration of the disease from 1 to 5 years was noted in 49% of patients, 6-10 years - in 26%, 10-15 years - in 14%, 16-18 years - in 11% of patients. The objective of our work was to evaluate the clinical efficacy, tolerability and safety of Kagocel® in the treatment of genital and labial herpes.
Keywords: treatment, genital and labial herpes
INTRODUCTION
Herpesvirus infection is one of the most common viral infections on our planet. According to statistics, about 98% of the world's population has been in contact with the herpes simplex virus (HSV) type I or II and has antibodies to it. To a greater extent (in 80% of cases), it is HSV type II that is the cause of the development of genital herpes. At the same time, there are more people infected with HSV type I than those infected with HSV type II: 3.7 billion and 536 million infected, respectively. In Russia, the incidence rate of genital herpes varies from 0.1 to 17.2 cases per 100,000 population, depending on the age group. In the United States, an average of 25% of pregnant women have antibodies to HSV type II, in Europe this figure is 16%, and in Asia - about 8%. In addition, about 5% of women get genital herpes for the first time during pregnancy. Statistics show the high relevance of this issue and the importance of its study by doctors of many specialties: obstetricians-gynecologists, dermatovenereologists, infectious disease specialists [1-3].
Central Asian Research Journal For Interdisciplinary Studies (CARJIS)
ISSN (online): 2181-2454 Volume 2 | Issue 10 |October, 2022 | SJIF: 5,965 | UIF: 7,6 | ISRA: JIF 1.947 | Google Scholar |
www.carjis.org DOI: 10.24412/2181-2454-2022-10-187-191
OBJECTIVE
To evaluate the clinical efficacy, tolerability and safety of Kagocel in the treatment of genital and labial herpes in a multicenter open controlled trial.
MATERIALS AND METHODS
A total of 146 patients were under observation, there were 63 men, 83 women. 23, over 50 years - 4. According to the PCR study, HSV-1 was detected in 30 (20.5%) patients, HSV-2 in 49 (33.5%), HSV-1 + HSV-2 in 23 ( 15.8%), HSV without type identification in 18 (12.3%), a negative result was obtained in 6 (4.1%), no study was conducted, in 20 (13.8%) patients. Genital herpes was in 115 patients, labial herpes in 31 patients. The duration of the disease from 1 to 5 years was noted in 49% of patients, 6-10 years - in 26%, 10-15 years - in 14%, 16-18 years - in 11% of patients. The frequency of recurrences of genital herpes per year was: 1-3 in 19 (16.5%) patients, 4-6 in 26 (22.5%), more than 6 in 65 (56.5%), not established in 5 (4.5%) patients; labial herpes: 1-3 - in 6 (19.4%), 4-6 - in 15 (48.4%), more than 6 -in 7 (22.6%), not established - in 3 (9.6%) %). For treatment, a tablet form of the Russian drug Kagocel (NEARMEDIK PLUS LLC) was used, containing 0.012 g of active substance per tablet. from cotton seeds. The drug is an active inducer of autologous interferon (IFN). "Kagocel" causes the formation in the human body of a mixture of "late" IFN- and - in close to physiological titers, which are known to have high antiviral activity. Patients were divided into 3 groups: patients of the 1st group received only "Kagocel" (106 patients), the second - "Kagocel" + acyclovir (10 patients), the third - only basic therapy with acyclovir (30 patients). Kagocel" in the primary episode and relapses was as follows: 2 tablets (0.012 g) three times a day for 5 days. Patients of the 3rd group with In the primary episode and relapses, acyclovir was prescribed in tablets of 0.2 g according to the following scheme: 1 tab. (0.2 g) 5 times a day for 5 days. Patients of the 2nd group received simultaneous treatment with "Kagocel" and acyclovir according to the indicated schemes.
Results
The severity of clinical signs - pain, itching, burning, epithelization of erosions, clearing of rashes - was assessed in points before treatment, on the 5th day of treatment and 10 days after its completion. A comparative analysis of the clinical evaluation of the effectiveness of treatment showed that the best results were obtained in patients of the first (Kagocel) and second (Kagocel + acyclovir) groups:
Central Asian Research Journal For Interdisciplinary Studies (CARJIS)
ISSN (online): 2181-2454 Volume 2 | Issue 10 |October, 2022 | SJIF: 5,965 | UIF: 7,6 | ISRA: JIF 1.947 | Google Scholar |
www.carjis.org DOI: 10.24412/2181-2454-2022-10-187-191
the evolution of clinical manifestations ended on days 5.6 and 3.2, respectively, while in 3 -th group, this period was 6.4 days. When observed for a year after treatment with "Kagocelom", no relapses were noted in 22.2%, 49.9% had one or two relapses, the rest (27.9%) had 3 relapses. In the treatment with acyclovir, the relapse rates were close to those of the 1st group: there were no relapses in 26.4%, 1-2 relapses in 41.2%, three relapses in 29.1%, more than 3 in 3.3% sick. However, the best result was obtained when both drugs were taken simultaneously: no relapse in 47.4%, 1-2 relapses in the remaining 52.6%. When evaluating the safety of Kagocel, none of the patients had side effects that required discontinuation of the drug, and there were no adverse events.
CONCLUSIONS
On the basis of the conducted research it was established: the use of the drug "Kagocel" in the treatment of herpes simplex leads to a complete regression of the clinical manifestations of the disease, a stable remission occurs and the number of relapses is reduced; the best results are obtained by the combined use of Kagocel with acyclovir; "Kagocel" is well tolerated by patients, does not cause the development of side effects.
REFERENCES
1. Аллахяров Д.З., Петров Ю.А., Аллахярова Н.В., Палиева Н.В. ГЕНИТАЛЬНЫЙ ГЕРПЕС: КЛИНИЧЕСКИЕ И ПАТОГЕНЕТИЧЕСКИЕ АСПЕКТЫ ЕГО ТЕЧЕНИЯ У БЕРЕМЕННЫХ // Современные проблемы науки и образования. - 2022. - № 4. ;
2. Hikmatovich I. N., Xolmatovich J. A., Axtamovna A. F. Applications of Elidel for Lichen Plane //Texas Journal of Medical Science. - 2022. - Т. 8. - С. 113-115.
3. Hikmatovich, I. N., Farmanovna, I. E., Amirovich, M. V., Temirovich, Y. R., & Mukumovich, A. D. (2021). Experience of Using Sevoran in The Treatment of Lichen Planus. International Journal of Innovative Analyses and Emerging Technology, 1(6), 69-70.
4. Hikmatovich, I. N., Xolmatovich, J. A., & Axtamovna, A. F. (2022). ATOPIK DERMATITLI BEMORLARNI PROGRESSIV BOSQICHDA MAHALLIY DAVOLASH SAMARADORLIGINI BAHOLASH. БАРКАРОРЛИК ВА ЕТАКЧИ ТАДКДКРТЛАР ОНЛАЙН ИЛМИЙ ЖУРНАЛИ, 259-263.
5. Hikmatovich, I. N., Xolmatovich, J. A., & Axtamovna, A. F. (2022).
Central Asian Research Journal For Interdisciplinary Studies (CARJIS)
ISSN (online): 2181-2454 Volume 2 | Issue 10 |October, 2022 | SJIF: 5,965 | UIF: 7,6 | ISRA: JIF 1.947 | Google Scholar |
www.carjis.org DOI: 10.24412/2181-2454-2022-10-187-191
O'SMIRLARDAGI VULGAR ACNE KASSALIGINI KOMPLEKS DAVOLASHNI ISHLAB CHIQISH VA SAMARADORLIKNI ANIQLASH. BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI, 323-326.
6. Azim, B., Davlat, A., Rustam, N., Rustam, O., Rustam, Y., Vasliddin, M., & Nurali, I. (2021). Analysis of the selection of the covering material for the treatment of thermal burn of the skin. European Journal of Molecular & Clinical Medicine, 8(3), 1785-1808.
7. Hikmatovich, I. N., Rajabboyevna, A. R., Ergashboyevna, A. Z., Temirovich, Y. R., & Uktamovich, T. S. (2021). Local Treatment of Children with Atopic Dermatitis. International Journal of Innovative Analyses and Emerging Technology, 1(5), 235237.
8. Hikmatovich, I. N., Baxodirovna, S. D., Ravshanovna, M. U., Temirovich, Y. R., & Davlatovich, A. X. (2021). The use of Fungite in the Local Treatment of Genital Herpes. International Journal of Innovative Analyses and Emerging Technology, 1(5), 231-232.
9. Hikmatovich, I. N., Baxodirovna, S. D., Ravshanovna, M. U., Temirovich, Y. R., & Davlatovich, A. X. (2021). The use of Fungite in the Local Treatment of Genital Herpes. International Journal of Innovative Analyses and Emerging Technology, 1(5), 231-232.
10. Исламов, Н. Х., Шадыев, У. Х., & Саламова, Л. А. (2011). Применение «Бетаметазон-Дарница» в лечении микробной экземы. Тюменский медицинский журнал, (2), 50-51.
11. Iskandarovna, K. M., Alamovich, K. A., & Rabbimovich, N. A. (2021). Treatment of Urethrogenic Prostatitis Associated with Chlamydia Infection. TA'LIM VA RIVOJLANISH TAHLILI ONLAYN ILMIY JURNALI, 1(5), 44-46.
12. Iskandarovna K. M., Buribaevna I. S., Azamovna A. N. Immunoassay Forms of Syphilis //TA'LIM VA RIVOJLANISH TAHLILI ONLAYN ILMIY JURNALI. -2021. - Т. 1. - №. 5. - С. 47-49.
13. Iskandarovna K. M. SIFILISNING IMMUNOASSAY SHAKLLARI //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. - 2022. - С. 534-536.
14. Ахмедова, М., Расулова, Н., & Абдуллаев, Х. (2016). Изучение парциальных функций почек у детей раннего возраста с нефропатией обменного генеза. Журнал проблемы биологии и медицины, (2 (87)), 37-40.
15. Нуруллаева, А. А., Рахматова, А. Х., & Абдуллаев, Х. Д. (2019). ЗНАЧЕНИЕ
Central Asian Research Journal For Interdisciplinary Studies (CARJIS)
ISSN (online): 2181-2454 Volume 2 | Issue 10 |October, 2022 | SJIF: 5,965 | UIF: 7,6 | ISRA: JIF 1.947 | Google Scholar |
www.carjis.org DOI: 10.24412/2181-2454-2022-10-187-191
МИКРОБНОГО ОБСЕМЕНЕНИЯ КОЖИ ПРИ НЕКОТОРЫХ ЗУДЯЩИХ ДЕРМАТОЗАХ. In Молодежь и медицинская наука в XXI веке (pp. 125-125). 16. Abdullaev, X. D., Xazratov, T. E., Tuxtaev, X. M., Mardonov, R. B., & Latipova, J. A. (2021). EVALUATION OF THE EFFECTIVENESS OF THE DRUG GEPON IN THE TREATMENT OF GENITAL CANDYLOMAS. Web of Scientist: International Scientific Research Journal, 1(02), 16-19.
